FDA warning letters for Indian firms relatively low at 12%
This article was originally published in Scrip
Executive Summary
In findings that might temper the debate on Indian manufacturing standards, an analysis of US FDA data for the 42-month period ended June 2013 has shown that a total of 66 firms, both innovator and generic, received warning letters, but that Indian companies accounted for just 12% of these.